Literature DB >> 18324970

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

Stefan O Ciurea1, Barry Sadegi, Andrew Wilbur, Victoria Alagiozian-Angelova, Sujata Gaitonde, Lisa C Dobogai, Luke P Akard, Ronald Hoffman, Damiano Rondelli.   

Abstract

Changes in spleen size postallogeneic haematopoietic stem cell transplantation (HSCT) in patients with primary myelofibrosis have been poorly characterized. We analysed 10 patients with myelofibrosis and splenomegaly following a reduced-intensity allogeneic HSCT. All patients fully engrafted donor cells including five patients with extensive splenomegaly. Extensive splenomegaly was associated with a prolonged time to neutrophil and platelet recovery. In all 10 patients, a progressive reduction of splenomegaly was documented within 12 months post-transplant and paralleled the reduction of marrow fibrosis. These findings suggest that myelofibrosis patients with extensive splenomegaly may proceed with allogeneic HSCT without prior splenectomy.

Entities:  

Mesh:

Year:  2008        PMID: 18324970     DOI: 10.1111/j.1365-2141.2008.07010.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

Review 1.  Therapy of myelofibrosis (excluding JAK2 inhibitors).

Authors:  Alessandro Rambaldi
Journal:  Int J Hematol       Date:  2010-02-24       Impact factor: 2.490

Review 2.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

Review 3.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

4.  JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Authors:  T Stübig; H Alchalby; M Ditschkowski; D Wolf; G Wulf; T Zabelina; C Wolschke; F Ayuk; N Kröger
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 5.  Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.

Authors:  Aravind Ramakrishnan; Brenda M Sandmaier
Journal:  Expert Rev Hematol       Date:  2010-02-01       Impact factor: 2.929

Review 6.  Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors:  Haefaa Alchalby; Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 7.  Rational therapeutic options for patients with myeloproliferative neoplasms.

Authors:  Ronald Hoffman
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

Review 8.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

9.  Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Authors:  David S Snyder; Joycelynne Palmer; Karl Gaal; Anthony S Stein; Vinod Pullarkat; Firoozeh Sahebi; Nyana Vora; Ryotaro Nakamura; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

10.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Authors:  Damiano Rondelli; Judith D Goldberg; Luis Isola; Leah S Price; Tsiporah B Shore; Michael Boyer; Andrea Bacigalupo; Alessandro Rambaldi; Marco Scarano; Rebecca B Klisovic; Vikas Gupta; Bjorn Andreasson; John Mascarenhas; Meir Wetzler; Alessandro M Vannucchi; Josef T Prchal; Vesna Najfeld; Attilio Orazi; Rona S Weinberg; Crystal Miller; Giovanni Barosi; Lewis R Silverman; Giuseppe Prosperini; Roberto Marchioli; Ronald Hoffman
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.